Exelixis, NCI to Study Anti-Cancer Compounds | GenomeWeb

SOUTH SAN FRANCISCO--Exelixis announced that it has signed a Cooperative Research and Development Agreement with the US National Cancer Institute to elucidate how NCI anti-cancer compounds work. In the three-year collaboration, Exelixis will use its proprietary model system genetics technology to identify the mechanism of action for NCI compounds that have a demonstrated in vivo or in vitro anti-cancer activity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.